Ranjana Advani
Academic Appointments
- Professor - Med Center Line, Medicine - Oncology
- Member, Stanford Cancer Institute
Key Documents
Contact Information
-
Clinical Offices
Lymphoma Clinic 875 Blake Wilbur Dr Clinic C Stanford, CA 94305 Tel Work (650) 498-6000 Fax (650) 725-9113
- Academic Offices
Alternate Contact Johnathan Eaglin Administrative Associate Email Tel Work 650-725-6456Not for medical emergencies or patient use
Professional Overview
Clinical Focus
- Lymphoma
- Burkitt's Lymphoma
- Burkitt's Lymphoma - Hematology
- Burkitt's Lymphoma - Medical Oncology
- Hodgkin's Disease
- Investigational Therapeutics
Administrative Appointments
- Lymphoma DMG leader, Stanford Cancer Institute (2010 - present)
Professional Education
| Residency: | Stanford University School of Medicine CA (1990) |
| Board Certification: | Medical Oncology, American Board of Internal Medicine (1995) |
| Internship: | Santa Clara Valley Medical Center, CA USA (1987) |
| Medical Education: | Bombay University, India (1982) |
Graduate & Fellowship Program Affiliations
Community and International Work
- Stanford Biomarkers Consortium&suffix=physician
Scientific Focus
Current Research Interests
Clinical investigation in Hodgkin's disease, non-Hodgkin's Lymphomas and cutaneous lymphomas. Experimental therapeutics with novel chemotherapy and biologically targeted therapies.
The research program is highly collaborative with radiation oncology, industry, pathology and dermatology.
Clinical Trials
- Not Recruiting Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia
- Not Recruiting Phase II Study of Bexxar in Relapsed/Refractory Diffuse Large Cell Lymphoma
- Recruiting Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL)
- Recruiting Pilot Study of Brentuximab Vedotin (SGN-35) in Patients With MF With Variable CD30 Expression Level
- Recruiting Genes in Predicting Outcome of Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab and Combination Chemotherapy
Publications
- Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol. 2013; (1): 88-94
- Efficacy of abbreviated Stanford V chemotherapy and involved-field radiotherapy in early-stage Hodgkin lymphoma: mature results of the G4 trial. Ann Oncol. 2013; (4): 1044-8
- Risk of therapy-related secondary leukemia in Hodgkin lymphoma: the Stanford University experience over three generations of clinical trials. J Clin Oncol. 2013; (5): 592-8
- Gene expression-based model using formalin-fixed paraffin-embedded biopsies predicts overall survival in advanced-stage classical Hodgkin lymphoma. J Clin Oncol. 2013; (6): 692-700
- Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). J Clin Oncol. 2013; (6): 684-91
- Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012; (18): 2190-6
Help
Trial Administration